IAM.US Iambic Therapeutics, Inc. Common Stock
- Market cap
- USD 621M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is IAM.US undervalued?
Graham numberThe Graham number of Iambic Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Iambic Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Iambic Therapeutics, Inc. Common Stock yet.
Iambic Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Iambic Therapeutics, Inc. Common Stock
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes …
Full company profileIambic Therapeutics, Inc. Common Stock financial statements
Iambic Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 |
|---|---|---|
| Income Statement | ||
| Revenue | 1.19M | 9.43M |
| Operating Income | -53.9M | -82.4M |
| EBITDA | -46.8M | -76.0M |
| Net Income | -47.9M | -77.3M |
| EPS | -1.01 | -1.63 |
| Balance Sheet | ||
| Total Assets | 156M | 195M |
| Total Liabilities | 268M | 382M |
| Shareholders' Equity | -112M | -187M |
| Cash & Short-term Investments | 142M | 181M |
| Cash Flow | ||
| Operating Cash Flow | -33.6M | -58.8M |
| Capital Expenditure | 707K | 1.28M |
| Free Cash Flow | -34.3M | -60.1M |
| Ratios | ||
| ROA | -30.7% | -39.6% |
| Net Profit Margin | -4,009.8% | -820.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Iambic Therapeutics, Inc. Common Stock dividends
Iambic Therapeutics, Inc. Common Stock has not paid dividends in the last 2 fiscal years.
Who owns Iambic Therapeutics, Inc. Common Stock
- Insiders 7.63%
- Institutions 26.16%
- Public & others 66.21%
- Shares outstanding 47.4M
- Free float 5.95M
Top funds holding IAM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARK Genomic Revolution ETF | 1.36M | 2.88% | +0.58% | Oct 2026 |
| ARK Genomic Revolution ETF A USD Acc | 76.2K | 0.16% | 0.00% | Oct 2026 |
| Tema Oncology ETF | 36.1K | 0.08% | 0.00% | Oct 2026 |
| Tema Healthcare AI ETF | 10.9K | 0.02% | 0.00% | Oct 2026 |
Iambic Therapeutics, Inc. Common Stock company profile
- Company name
- Iambic Therapeutics, Inc. Common Stock
- Ticker
- IAM.US
- Exchange
- USA Stocks
- Listed since
- Oct 15, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 171
- Fiscal year end
- December
- Address
- 5627 Oberlin Drive, San Diego, CA, United States, 92121
- Phone
- (619) 330-5499
- Website
- iambic.ai
About Iambic Therapeutics, Inc. Common Stock
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.
Iambic Therapeutics, Inc. Common Stock management
8- Dr. Thomas Miller Ph.D.Co-Founder, CEO, Secretary & Director · born 1979
- Mr. Frederick R. Manby Ph.D.Co-Founder, CTO & Director · born 1972
- Dr. Michael Secora Ph.D.Chief Corporate Development Officer & CFO · born 1983
- Dr. Peter A. Olson Ph.D.Chief Scientific Officer · born 1974
- Ms. Sunny Chang J.D.General Counsel
- Dr. Neil Josephson M.D.Chief Medical Officer · born 1961
- Mr. Laurent Gomez Ph.D.Senior VP & Head of Discovery
- Mr. Matt Welborn Ph.D.Senior Vice President of Machine Learning